L3VLUP
ProSign in

RMD · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RMDLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RMD
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterRMDLLY
Q3 202015 holders, $3.0bn33 holders, $14.1bn
Q4 20209 holders, $3.7bn29 holders, $17.3bn
Q1 202110 holders, $2.9bn24 holders, $23.0bn
Q2 202112 holders, $3.7bn24 holders, $27.8bn
Q3 202115 holders, $4.2bn31 holders, $29.9bn
Q4 202118 holders, $3.5bn31 holders, $34.7bn
Q1 202210 holders, $4.0bn24 holders, $35.3bn
Q2 202211 holders, $3.4bn33 holders, $42.7bn
Q3 202213 holders, $3.9bn31 holders, $43.4bn
Q4 202219 holders, $3.7bn31 holders, $46.6bn
Q1 202321 holders, $3.9bn33 holders, $44.3bn
Q2 202326 holders, $3.7bn37 holders, $59.6bn
Q3 202317 holders, $1.9bn44 holders, $67.6bn
Q4 202310 holders, $1.0bn45 holders, $73.6bn
Q1 20248 holders, $513m41 holders, $95.3bn
Q2 20249 holders, $574m43 holders, $110bn
Q3 202411 holders, $1.0bn45 holders, $107bn
Q4 20249 holders, $914m46 holders, $93.9bn
Q1 20259 holders, $844m42 holders, $98.4bn
Q2 20257 holders, $810m43 holders, $93.2bn
Q3 20258 holders, $1.1bn39 holders, $86.7bn
Q4 202511 holders, $1.0bn41 holders, $123bn
Q1 20269 holders, $919m39 holders, $106bn
Q2 202613 holders, $1.1bn44 holders, $132bn
RMD

Resmed Inc

Holders
9
Reported value
$844m
Buyers
7
Sellers
3

Breadth +4 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
42
Reported value
$98.4bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RMD (3)

PDT Partners LLC, Quantbot Technologies LP, Squarepoint Ops LLC

Only LLY (36)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Lone Pine Capital LLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, and 11 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →